Charles River Laboratories International Inc (CRL) Actualités

Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call

Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2024 financial results and provide 2025...

Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences

Launch of Apollo™ for CRADL® provides a secure cloud-based platform to enhance access to services and visibility across teams and processes...

Charles River and Akron Bio Announce Collaboration to Enhance Operations with Integration of CGMP Materials into Cell Therapy Platform

Charles River Laboratories International, Inc. (NYSE: CRL) and Akron Bio (“Akron”), a leading supplier of critical materials and services for...

Form 8-K - Current report

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 43rd Annual J.P. Morgan Healthcare...

Form 8-K - Current report

Charles River Introduces Global Biotech Incubator Program

Program offers biotechnology developers access to extensive scientific expertise and a wide ecosystem of discovery, development and manufacturing...

Charles River Laboratories to Present at Evercore ISI Investor Conference

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 7th Annual Evercore ISI HealthCONx...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Charles River Laboratories to Present at UBS and Jefferies Conferences

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the UBS Global Healthcare Conference on...

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]